Dermatophytosis ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Dermatophytosis ' Pipeline Review, H2 2012
Published on August 2012

Report Summary


Summary

Global Markets Direct's, 'Dermatophytosis - Pipeline Review, H2 2012', provides an overview of the Dermatophytosis therapeutic
pipeline. This report provides information on the therapeutic development for Dermatophytosis, complete with latest updates, and
special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for
Dermatophytosis. 'Dermatophytosis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets
Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Dermatophytosis.
- A review of the Dermatophytosis products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dermatophytosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development
progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dermatophytosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dermatophytosis pipeline depth and focus of Dermatophytosis
therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Dermatophytosis ' Pipeline Review, H2 2012 (From Slideshare) Page 1/6


Table of Content

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dermatophytosis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Dermatophytosis 7
Dermatophytosis Therapeutics under Development by Companies 9
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Early Clinical Stage Products 13
Pre-Clinical Stage Products 14
Dermatophytosis Therapeutics ' Products under Development by Companies 15
Companies Involved in Dermatophytosis Therapeutics Development 16
Valeant Pharmaceuticals International 16
Stiefel Laboratories, Inc. 17
Quinnova Pharmaceuticals, Inc. 18
Bayer AG 19
Helix BioMedix, Inc. 20
Almirall, S.A. 21
Anacor Pharmaceuticals, Inc. 22
Nitric Biotherapeutics, Inc. 23
Laboratorio Teuto Brasileiro 24
Dermatophytosis ' Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
HB1275 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
IDP 113 - Drug Profile 31
R&D Progress 31
AN2718 - Drug Profile 32



R&D Progress 32
Albaconazole - Drug Profile 33
R&D Progress 33
LAS41003 - Drug Profile 35
R&D Progress 35
Nitric Oxide - Drug Profile 36
R&D Progress 36
Econazole Nitrate Foam 1% - Drug Profile 38
R&D Progress 38
Bifonazol Spray - Drug Profile 39
R&D Progress 39
Tolnaftate - Drug Profile 40
R&D Progress 40
Dermatophytosis Therapeutics ' Drug Profile Updates 41
Dermatophytosis Therapeutics - Dormant Products 42
Dermatophytosis ' Product Development Milestones 43
Featured News & Press Releases 43
Apr 12, 2006: Medicis Announces Two Patents Issued for Loprox Gel 43
Apr 12, 2006: Medicis Announces Two Patents Issued for Loprox Gel 43
Dec 20, 1999: Medicis Announces FDA Approval of Loprox Gel, 0.77% 43
Dec 20, 1999: Medicis Announces FDA Approval of Loprox Gel, 0.77% 43
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables

Number of Products Under Development for Dermatophytosis, H2 2012 7
Products under Development for Dermatophytosis ' Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 10



Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Valeant Pharmaceuticals International, H2 2012 16
Stiefel Laboratories, Inc., H2 2012 17
Quinnova Pharmaceuticals, Inc., H2 2012 18
Bayer AG, H2 2012 19
Helix BioMedix, Inc., H2 2012 20
Almirall, S.A., H2 2012 21
Anacor Pharmaceuticals, Inc., H2 2012 22
Nitric Biotherapeutics, Inc., H2 2012 23
Laboratorio Teuto Brasileiro, H2 2012 24
Assessment by Monotherapy Products, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 29
Dermatophytosis Therapeutics ' Drug Profile Updates 41
Dermatophytosis Therapeutics ' Dormant Products 42

List of Figures

Number of Products under Development for Dermatophytosis, H2 2012 7
Products under Development for Dermatophytosis ' Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 25
Assessment by Route of Administration, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Molecule Type, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 29


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Dermatophytosis ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Dermatophytosis ' Pipeline Review, H2 2012